Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions demonstrate high interest through mentions of the 5-year follow-up and overall significance of outcomes, with some comments referencing the detailed methodology and potential influence on clinical practice, showing a moderate level of engagement and recognition of impact.
Most discussions acknowledge the study results, highlighting that both PCI and CABG have similar long-term outcomes, indicating general agreement with the findings.
Participants show high interest, often referencing key aspects like 5-year follow-up and significance for treatment decisions, which suggests engagement with the clinical implications.
There are mentions of details like the trial's multicenter design and calls for further research, indicating moderate to deep engagement beyond surface-level commentary.
Some discussions emphasize the importance of the study for future clinical guidelines and practice, reflecting a moderate impact perception.
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial https://t.co/a3xAnYGTOB https://t.co/ryWfDTjdsX
Best ACC 2025 Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting 5-year follow-up no significant difference in a composite outcome of death, stroke, or myocardial infarction https://t.co/UEvyCg5QIn
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up At the 5-year follow-up, there was no significant difference of death, stroke, or myocardial infarction https://t.co/UEvyCg5iSP
✨Great evidence summaries in a unique format! Subscribe to the YouTube channel Evidence-Based Cardiology Talks
RT @latidoscc:
The FAME 3 trial analyzed long-term outcomes of FFR-guided PCI versus CABG in multivessel coronary artery disease over five years, showing similar rates of major adverse events for both treatments.
This Lancet article presents the fiveyear followup results of the FAME 3 trial. It compares fractional flow reserve-guided PCI with the latest-generation stents and coronary artery bypass grafting in patients with…
This Lancet article presents the five-year follow-up results of the FAME 3 trial, which compared FFR-guided PCI using latest-generation stents and coronary artery bypass grafting in patients with three-vessel disease…
RT @latidoscc:
New from @TheLancet Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3) #AbbottCardiovascular #OmniWire #Philips #pressurewire contact me for reprints https://t.co/3zssYZkMU3
RT @TheLancet: Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAM…
RT @TheLancet: Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAM…
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial https://t.co/a3xAnYGTOB https://t.co/ryWfDTjdsX
✨Great evidence summaries in a unique format! Subscribe to the YouTube channel Evidence-Based Cardiology Talks
"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial." Publié ce jour dans @thelancet.bsky.social #MedSky #CardioSky www.thelancet.com/journals/lan...
FFRガイドのPCIはCABGと比較して死亡、脳卒中、心筋梗塞の複合アウトカムに有意差はなかった。MIや血行再建はPCIで多かった。FAME3試験。Lancet. PMID: 40174598. https://t.co/yzRUMwobqM
[Articles] Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial https://t.co/RJrM7LyYLq
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial
Best ACC 2025 Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting 5-year follow-up no significant difference in a composite outcome of death, stroke, or myocardial infarction https://t.co/UEvyCg5QIn
[Articles] Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial #science #publication #research #publications https://t.co/uojE3irfEK
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial - The Lancet https://t.co/2OTRY0zFQs
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up At the 5-year follow-up, there was no significant difference of death, stroke, or myocardial infarction https://t.co/UEvyCg5iSP